Jasper Therapeutics, Inc. (JSPR)
NASDAQ: JSPR · Real-Time Price · USD
22.05
+0.21 (0.96%)
Nov 22, 2024, 4:00 PM EST - Market closed
Jasper Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Selling, General & Admin | 18.8 | 17.08 | 16.57 | 11.41 | 4.8 | 1.09 |
| Research & Development | 49.88 | 51.79 | 34.63 | 25.42 | 15.88 | 3.62 |
| Operating Expenses | 68.68 | 68.86 | 51.2 | 36.83 | 20.68 | 4.71 |
| Operating Income | -68.68 | -68.86 | -51.2 | -36.83 | -20.68 | -4.71 |
| Interest Expense | - | - | - | - | - | -0.53 |
| Interest & Investment Income | 5.35 | 5.2 | 0.7 | - | - | - |
| Other Non Operating Income (Expenses) | -0.23 | -0.82 | 7.09 | -3.08 | -10.99 | 0.26 |
| EBT Excluding Unusual Items | -63.56 | -64.48 | -43.41 | -39.91 | -31.67 | -4.99 |
| Other Unusual Items | 0.03 | 0.02 | 5.73 | 9.28 | - | - |
| Pretax Income | -63.53 | -64.47 | -37.69 | -30.64 | -31.67 | -4.99 |
| Net Income | -63.53 | -64.47 | -37.69 | -30.64 | -31.67 | -4.99 |
| Net Income to Common | -63.53 | -64.47 | -37.69 | -30.64 | -31.67 | -4.99 |
| Shares Outstanding (Basic) | 14 | 10 | 4 | 1 | 0 | - |
| Shares Outstanding (Diluted) | 14 | 10 | 4 | 1 | 0 | - |
| Shares Change (YoY) | 58.22% | 186.15% | 220.19% | 558.67% | - | - |
| EPS (Basic) | -4.67 | -6.18 | -10.33 | -26.89 | -183.08 | - |
| EPS (Diluted) | -4.67 | -6.18 | -10.33 | -26.89 | -183.08 | - |
| Free Cash Flow | -58.63 | -52.33 | -46.43 | -36.11 | -18.27 | -1.97 |
| Free Cash Flow Per Share | -4.31 | -5.01 | -12.73 | -31.69 | -105.60 | - |
| EBITDA | -67.27 | -67.75 | -50.22 | -36.46 | - | - |
| D&A For EBITDA | 1.41 | 1.11 | 0.98 | 0.38 | - | - |
| EBIT | -68.68 | -68.86 | -51.2 | -36.83 | -20.68 | -4.71 |
Source: S&P Capital IQ. Standard template.
Financial Sources.